Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
September 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
September 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
December 2015 Vol 8, No 9
Editorial
PEACE Time
David B. Nash, MD, MBA
Read More
Letters to the Editor
Correspondence: Cost of Treatment for Relapsed/Refractory Multiple Myeloma
Read More
Business
,
Original Research
Anticipated Impact of Generic Imatinib Market Entry on the Costs of Tyrosine Kinase Inhibitors
Lisa M. Bloudek, PharmD, MS
,
Dinara Makenbaeva, MD, MBA
,
Michael Eaddy, PharmD, PhD
Stakeholder Perspective
Generic Imatinib: Can It Provide Significant Cost Relief for Patients?
by
Gary Branning, MBA
Read More
Clinical
The PCSK9 Inhibitors: A Novel Therapeutic Target Enters Clinical Practice
Norman E. Lepor, MD
,
Dean J. Kereiakes, MD
Read More
Perspectives
Employers Engaged in Benefit Design Innovation: Long-Term Trends in a 2015 National Survey
Cheryl Larson
,
F. Randy Vogenberg, PhD, FASHP
Read More
Clinical
,
Original Research
Novel Adherence Measures for Infusible Therapeutic Agents Indicated for Rheumatoid Arthritis
Joseph Tkacz, MS
,
Michael P. Ingham, MSc
,
Brenna L. Brady, PhD
,
Roxanne Meyer, PharmD
,
Charles Ruetsch, PhD
Stakeholder Perspective
You Cannot Manage What You Cannot Measure
by
Sharon Glave Frazee, PhD, MPH
Read More
Results 1 - 6 of 6